There are a number of different hypolipidmmic agents available at present. Their efficacy in various types of hyperlipideemias varies, and none is consistently beneficial. This has led to highly divergent opinions, in both practical and theoretical terms, of their action and therapeutic significance in the treatment of hyperlipidcmias (Hunninghake et al. 1969 , Levy 1975 , Gustafson 1975 . New hypolipidwmic agents are obviously needed. Such agents should always be compared with the current ones for the interpretation of their efficacy. In this study a new hypolipideemic agent, gemfibrozil, was compared in a cross-over study with clofibrate in the treatment of primary hyperlipidwmia.
Patients and Methods
A total of 22 adult outpatients volunteered for the trial. All had either serum cholesterol above 300 mg/100 ml, triglycerides above 200 mg/100 ml, or both. Secondary hyperlipidamias caused by the nephrotic syndrome, hypothyroidism, diabetes or liver diseases were excluded after clinical examination and laboratory tests. The volunteers used no drugs known to affect lipid levels. According to Fredrickson's classification, 6 subjects were of type Ila, 13 of Ilb and 3 of type IV hyperlipidcemia.
Having fulfilled the above selection/exclusion criteria, the subjects were treated with placebo for two weeks. During this run-in period, blood samples were taken three times (Days 1, 7 and 14) to establish the non-treatment baseline. All blood samples were taken after a 12-hour fast. After this run-in period the subjects were randomly selected and treated either with gemfibrozil at 800 mg daily or with clofibrate at 1500 mg daily for six weeks. All members of both groups were then given placebo for four weeks and for the last stage were switched to the other active drug for six weeks.
To establish the efficacy and safety of both treatments the laboratory investigations included, besides the lipid analyses, the following tests: ESR (Westergren), blood hemoglobin, hmmatocrit, red and white cell counts, and serum GPT, bilirubin, alkaline phosphatase, creatine kinase (CK), and creatinine. Urinalysis and ECG recordings were also performed.
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Serum cholesterol was measured according to Pearson et a. (1953) , triglycerides with the Auto Analyzer method, and Boehringer reagent kits were used to determine the serum enzyme activities.
The ages of the subjects ranged from 30 to 62 years, the mean being 49.9 years. There were 10 males and 12 females. The family histories revealed close relatives suffering from documented hyperlipidemia in 10 cases. In 6 subjects coronary heart disease was diagnosed, 7 others were hypertensive, and 9 subjects were symptom-free. Four had x4nthomatosis.
The subjects were instructed to continue with their normal diets and living habits as far as possible. The subjects did not know whether they were receiving the active compounds or the placebo.
Results
The individual values for serum cholesterol and triglycerides before and after both active treatment periods are shown in Figs 1-4. Eleven subjects in all had serum triglyceride levels above 200 mg/100 ml at the beginning of the gemfibrozil treatment. In 9 of them triglycerides were decreased to within the normal range at some time during the treatment period. In 7 subjects the serum triglyceride levels stayed within the normal range throughout the treatment period. Of the 8 subjects with high initial triglycerides before the clofibrate period, serum triglycerides were reduced in 5 to within the normal range during the course of treatment. Only in 3 subjects did a satisfactory response fail to appear to both drugs. The mean reduction in the serum triglyceride level was more pronounced during both gemfibrozil periods (Fig 5) , although the difference was not statistically significant.
Nineteen patients in all had serum cholesterol levels above 300 mg/100 ml before either treatment. During gemfibrozil periods, 11 subjects manifested cholesterol reductions to within the normal range. The results were similar with clofibrate. Cholesterol failed to fall below 300 mg/ 100 ml in 7 subjects during either clofibrate or gemfibrozil treatment. Among them were 3 who responded favourably to either of the two treatments while being non-responders to the alternative treatment. One subject did not respond to either gemfibrozil or clofibrate. The mean reduction was similar with both active compounds ( Fig 6) .
The most prominent decrease in the serum triglyceride level was seen among type IIb subjects (the maximum reduction being 59.9 % with gemfibrozil and 51.5 % with clofibrate).
There was a clear difference in the nature of the decrease of lipid levels caused by the active compounds (Fig 7) . The reductions due to gemfibrozil in cholesterol and triglycerides seemed to be correlated (r=0.566, P<0.05) to some extent, while those caused by clofibrate showed no such correlation.
Variations in the weights of the subjects during the course of the trial were less than 2 kg except for 1 subject who lost 4 kg and another who gained 4 kg. Thus the mean weight of the group remained stable throughout the study period.
Hmmatology, serum GPT, CK and creatinine, and urinalysis indicated no evidence of organ toxicity with either drug, and there were no adverse clinical reactions.
DISCUSSION
The accurate comparison of the hypolipidwmic effect of two compounds assumes certain arrangements in the trial design. Firstly, for the exclusion of individual differences in response to the drug, the subject has to be his own control. Secondly, the wash-out period should be long enough to neutralize the effect of the previous compound. Lastly, stabilization of exogenous environmental factors known to affect lipid levels should be attempted throughout the trial. In the present study the wash-out period between the two active treatment periods was sufficient for the return of the cholesterol and triglyceride values to pretreatment levels. The study was also of a cross-over design. All volunteers attended the trial almost simultaneously, making the consideration of seasonal variation in lipid levels unnecessary in the comparison between clofibrate and gemfibrozil.
It has been suggested that the lipid level is affected by psychological factors, e.g. voluntary or unconscious changes in the diet. Therefore, the importance of a placebo as a control has been emphasized (Levy 1975 (Levy 1975) . In the present study the subjects were treated with placebo during the wash-out period although they did not know this. The return of the lipid levels to their initial values was complete and without significant rebound, indicating that the design of the present study was suitable for realistic comparison of gemfibrozil and clofibrate. In the analysis of the mean values of serum cholesterol and triglycerides it was not possible to distinguish at a significant level between the efficacy of 800 mg of gemfibrozil daily and 1500 mg of clofibrate daily in lowering serum cholesterol or triglyceride levels. However, there was a tendency for the fall in triglyceride values to be more pronounced with gemfibrozil. The findings of re- sponders to gemfibrozil among the non-responders to clofibrate and vice versa indicates that gemfibrozil may prove useful in the treatment of hyperlipidwmias and should be made available. Gemfibrozil itself is a hypolipidemic drug that is well tolerated without adverse reactions. In this respect it is similar to clofibrate. The one clear difference between gemfibrozil and clofibrate in the present study was the more marked interrelationship between reductions in cholesterol and triglycerides with gemfibrozil. If this is a sign of differing modes of action of these drugs, further investigations are indicated.
